Roche: 2017 sales up 5%
(CercleFinance.com) - Roche, the Swiss pharmaceutical giant which is well known for its exposure to oncology, reported sales that were up 5% last year, both as reported and at constant exchange rates, totaling 53.
3 billion Swiss francs.
The majority Pharma and Diagnostics divisions both reported the same growth.
Meanwhile, core operating profit (adjusted) rose 3%, in current data and at constant exchange rates, to 19 billion Swiss francs, with the group's core net income rose by 6% (+5% excluding FX factors), to 15.34 Swiss francs per share.
However, due to the deterioration of goodwill and intangible assets, IFRS net book result decreased by 9% to 8.8 billion francs.
For 2018, Roche targets sales growth of up to 5% at constant exchange rates. Under equivalent terms, adjusted EPS is expected to rise by up to 10%. The group finally intends to increase its dividend in Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
3 billion Swiss francs.
The majority Pharma and Diagnostics divisions both reported the same growth.
Meanwhile, core operating profit (adjusted) rose 3%, in current data and at constant exchange rates, to 19 billion Swiss francs, with the group's core net income rose by 6% (+5% excluding FX factors), to 15.34 Swiss francs per share.
However, due to the deterioration of goodwill and intangible assets, IFRS net book result decreased by 9% to 8.8 billion francs.
For 2018, Roche targets sales growth of up to 5% at constant exchange rates. Under equivalent terms, adjusted EPS is expected to rise by up to 10%. The group finally intends to increase its dividend in Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.